HanAll Biopharma (KRX: 009420) focuses on the research and development of biopharmaceuticals that can be a source of hope for patients with rare and incurable diseases who are suffering from no proper treatment. HanAll Biopharma is researching and de...Show all
Company (IPO / Went public)
Phone:
Daewoong Building 3F
12, Bongeunsa-ro 114-gil, Gangnam-gu
Seoul, 06170
South Korea
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Antibody binding to fcrn for treating autoimmune diseases | Apr 30, 2015 | Jan 28, 2020 | Patent |
Antibody binding to fcrn for treating autoimmune diseases | Apr 05, 2017 | Jul 02, 2019 | Patent |
Fcrn-specific human antibody and composition for treatment of autoimmune diseases | Jun 20, 2014 | May 07, 2019 | Patent |
Biguanide compounds and use thereof | Oct 30, 2014 | Mar 05, 2019 | Patent |
N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | Feb 06, 2014 | Feb 06, 2018 | Patent |